Biotech RadarJobs updated

COMPANY

TerSera Therapeutics

HQ: Deerfield, IL source · tersera.com ↗

Status: Acquired, now part of GTCR · How status works

Clinical Phase 2

3 open jobs · last seen Oct 23, 2026 · 4 sources

Location: Deerfield, IL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Advanced Breast Cancer Early Breast Cancer HER2-positive Breast Cancer HER2-positive Carcinoma Carcinoid Syndrome Biliary Tract Cancer ZOLADEX Margetuximab Xermelo telotristat ethyl

3Open jobs5Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Rare Disease SpecialistRemote Worker - Dallas / HoustonSep 9, 2026Oct 16, 2026
Specialty Account Manager - BostonRemote Worker - BostonAug 4, 2026Oct 16, 2026
Specialty Account Manager - Columbus, OHRemote Worker - ColumbusMay 26, 2026Oct 16, 2026

See all 3 jobs

Timeline

  1. Trial start Phase 1: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer source ↗
  2. Trial start 2: Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine source ↗
  3. Trial start Phase 2: A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer source ↗
  4. Trial start —: Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07310420A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerPhase 1RecruitingOct 30, 2026Mar 30, 2027 (estimated)
NCT03133988Margetuximab Expanded Access ProgramNot listedApproved for marketingNot listedNot listed
NCT03223428Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELONot listedCompletedJun 22, 2017Jan 14, 2022 (actual)
NCT04189588Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine2CompletedMar 25, 2020Nov 23, 2020 (actual)
NCT03790111A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract CancerPhase 2TerminatedMar 13, 2019Jan 13, 2022 (actual)

Open jobs 3

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Rare Disease SpecialistRemote Worker - Dallas / HoustonSep 9, 2026Oct 16, 2026Senior
Specialty Account Manager - BostonRemote Worker - BostonAug 4, 2026Oct 16, 2026Mid
Specialty Account Manager - Columbus, OHRemote Worker - ColumbusMay 26, 2026Oct 16, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at TerSera Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback